Retraction Note: A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo

Yu-Yin Xu^#^{1

2}, Li Chen^#³, Gui-Lan Wang¹, Jia-Ming Zhou¹, Yi-Xin Zhang⁴, Yin-Ze Wei⁴, Yuan-Yuan Zhu⁵, Jing Qin¹

Affiliations

¹ Department of Pathological Anatomy, Nantong University, Nantong, China.
² Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
³ Department of Pathological Anatomy, Nantong University, Nantong, China. bl1@ntu.edu.cn.
⁴ Department of Pathology, Affiliated Tumor Hospital, Nantong University, Nantong, China.
⁵ Biomics (Nantong) Co., Ltd, Nantong, China.

^# Contributed equally.

Yu-Yin Xu et al. BMC Cancer. 2023.

. 2023 Jul 7;23(1):636.

doi: 10.1186/s12885-023-11135-3.

Yu-Yin Xu^#^{1

2}, Li Chen^#³, Gui-Lan Wang¹, Jia-Ming Zhou¹, Yi-Xin Zhang⁴, Yin-Ze Wei⁴, Yuan-Yuan Zhu⁵, Jing Qin¹

¹ Department of Pathological Anatomy, Nantong University, Nantong, China.
² Department of Nephrology, Affiliated Hospital of Nantong University, Nantong, Jiangsu, China.
³ Department of Pathological Anatomy, Nantong University, Nantong, China. bl1@ntu.edu.cn.
⁴ Department of Pathology, Affiliated Tumor Hospital, Nantong University, Nantong, China.
⁵ Biomics (Nantong) Co., Ltd, Nantong, China.

^# Contributed equally.

No abstract available

Retraction of

A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo.
Xu YY, Chen L, Wang GL, Zhou JM, Zhang YX, Wei YZ, Zhu YY, Qin J. Xu YY, et al. BMC Cancer. 2013 Nov 6;13:527. doi: 10.1186/1471-2407-13-527. BMC Cancer. 2013. Retraction in: BMC Cancer. 2023 Jul 7;23(1):636. doi: 10.1186/s12885-023-11135-3. PMID: 24195809 Free PMC article. Retracted.

1. Chen, L., Xu, Y., Zhou, J., Wu, Y., E, Q., Zhu, Y. “TLR3 dsRNA agonist inhibits growth and invasion of HepG2.2.15 HCC cells”. Oncology Reports 28.1 (2012): 200–206. - PubMed